Abstract:Disability in multiple sclerosis is generally classified by sensory and motor symptoms, yet cognitive impairment has been identified as a frequent manifestation already in the early disease stages. Imaging- and more recently blood-based biomarkers have become increasingly important for understanding cognitive decline associated with multiple sclerosis. Thus, we sought to determine the prognostic utility of serum neurofilament light chain levels alone and in combination with MRI markers by examining their ability to predict cognitive impairment in early multiple sclerosis. A comprehensive and detailed assessment of 152 early multiple sclerosis patients (Expanded Disability Status Scale: 1.3 ± 1.2, mean age: 33.0 ± 10.0 years) was performed, which included serum neurofilament light chain measurement, MRI markers (i.e. T2-hyperintense lesion volume and grey matter volume) acquisition and completion of a set of cognitive tests (Symbol Digits Modalities Test, Paced Auditory Serial Addition Test, Verbal Learning and Memory Test) and mood questionnaires (Hospital Anxiety and Depression scale, Fatigue Scale for Motor and Cognitive Functions). Support vector regression, a branch of unsupervised machine learning, was applied to test serum neurofilament light chain and combination models of biomarkers for the prediction of neuropsychological test performance. The support vector regression results were validated in a replication cohort of 101 early multiple sclerosis patients (Expanded Disability Status Scale: 1.1 ± 1.2, mean age: 34.4 ± 10.6 years). Higher serum neurofilament light chain levels were associated with worse Symbol Digits Modalities Test scores after adjusting for age, sex Expanded Disability Status Scale, disease duration and disease-modifying therapy (B = -0.561; SE = 0.192; P = 0.004; 95% CI = -0.940 to -0.182). Besides this association, serum neurofilament light chain levels were not linked to any other cognitive or mood measures (all P-values > 0.05). The tripartite combination of serum neurofilament light chain levels, lesion volume and grey matter volume showed a cross-validated accuracy of 88.7% (90.8% in the replication cohort) in predicting Symbol Digits Modalities Test performance in the support vector regression approach, and outperformed each single biomarker (accuracy range: 68.6-75.6% and 68.9-77.8% in the replication cohort), as well as the dual biomarker combinations (accuracy range: 71.8-82.3% and 72.6-85.6% in the replication cohort). Taken together, early neuro-axonal loss reflects worse information processing speed, the key deficit underlying cognitive dysfunction in multiple sclerosis. Our findings demonstrate that combining blood and imaging measures improves the accuracy of predicting cognitive impairment, highlighting the clinical utility of cross-modal biomarkers in multiple sclerosis.

Serum and cerebrospinal fluid BDNF concentrations are associated with neurological and cognitive improvement in multiple sclerosis: A pilot study

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis

Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis

Improved prediction of early cognitive impairment in multiple sclerosis combining blood and imaging biomarkers

High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis

Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis

The potential of serum neurofilament as biomarker for multiple sclerosis

Brain derived neurotrophic factor in multiple sclerosis: effect of 24 weeks endurance and resistance training

In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting

Serum Vitamin D3 as a Potential Biomarker for Neuronal Damage in Smoldering Multiple Sclerosis

Increased plasma brain-derived neurotrophic factor (BDNF) as a potential biomarker for and compensatory mechanism in mild cognitive impairment: a case-control study

Investigation of Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor Concentrations in Serum and Cerebrospinal Fluid of Patients with Multiple Sclerosis and Neuromyelitis Optica

Serum NfL and GFAP are weak predictors of long-term multiple sclerosis prognosis: a 6-year follow-up.

Predicting clinical progression and cognitive decline in patients with relapsing-remitting multiple sclerosis: a 6-year follow-up study

Targeted proteomics of cerebrospinal fluid in treatment naïve multiple sclerosis patients identifies immune biomarkers of clinical phenotypes

Changes in BDNF methylation patterns after cognitive remediation therapy in schizophrenia: A randomized and controlled trial

Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a post hoc analysis

Cognitive deficit is related to immune-cell beta-NGF in multiple sclerosis patients

Low BDNF is Associated with Cognitive Impairment in Chronic Patients with Schizophrenia

Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis

Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes